Compositions and methods for the treatment of skin

Details Compositions and methods for the treatment of skin Compositions and methods for the treatment of skin

2008-01-16

2010-11-16

Richter, Johann R (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S062000

Reexamination Certificate

active

07834055

ABSTRACT:
An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid formulated to have a pH above 3.5. 10 to50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and/or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.

REFERENCES:
patent: 2400171 (1946-05-01), Ruskin et al.
patent: 2442461 (1948-06-01), Karrer
patent: 2517276 (1950-08-01), Bassford et al.
patent: 2585580 (1952-02-01), Oppit
patent: 3857939 (1974-12-01), Green et al.
patent: 3857970 (1974-12-01), Tsumura et al.
patent: 3886265 (1975-05-01), Evers et al.
patent: 4229430 (1980-10-01), Fahim et al.
patent: 4294852 (1981-10-01), Wildnauer et al.
patent: 4367157 (1983-01-01), Sherman
patent: 4515771 (1985-05-01), Fine
patent: 4590067 (1986-05-01), Meisner
patent: 4647453 (1987-03-01), Meisner
patent: 4711780 (1987-12-01), Fahim
patent: 4722936 (1988-02-01), Jacob
patent: 4772591 (1988-09-01), Meisner
patent: 4818521 (1989-04-01), Tamabuchi
patent: 4894978 (1990-01-01), Schonmann et al.
patent: 4938969 (1990-07-01), Schinitsky et al.
patent: 4983382 (1991-01-01), Wilmott et al.
patent: 5140043 (1992-08-01), Darr et al.
patent: 5308621 (1994-05-01), Taylor et al.
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5358990 (1994-10-01), Woodard et al.
patent: 5516793 (1996-05-01), Duffy
patent: 5554647 (1996-09-01), Perricone
patent: 5681852 (1997-10-01), Bissett
patent: 5700451 (1997-12-01), Yue et al.
patent: 5703122 (1997-12-01), Duffy
patent: 5736567 (1998-04-01), Cantin et al.
patent: 5750123 (1998-05-01), Znaiden et al.
patent: 5804594 (1998-09-01), Murad
patent: 5902591 (1999-05-01), Herstein
patent: 5972993 (1999-10-01), Ptchelintsev
patent: 6217914 (2001-04-01), Meisner
patent: 6440465 (2002-08-01), Meisner
patent: 6444699 (2002-09-01), Meisner
patent: 2001/0041193 (2001-11-01), Meisner
patent: 2002/0031557 (2002-03-01), Meisner
patent: 2002/0164386 (2002-11-01), Meisner
patent: 2005/0003023 (2005-01-01), Meisner
patent: 2006/0165819 (2006-07-01), Meisner
patent: 281812 (1988-09-01), None
patent: 0273202 (1995-06-01), None
patent: 0771557 (1999-08-01), None
patent: 61078715 (1986-04-01), None
patent: WO 98/23152 (1998-06-01), None
patent: WO 00/56327 (2000-09-01), None
patent: WO 01/83031 (2001-11-01), None
patent: WO 01/83031 (2002-04-01), None
Remington's Pharmaceutical Sciences (17th Ed. 1985), p. 1293.
English Language Translation of EP 0771557 (2010).
Setnikar, “Antireactive properties of glucosamine sulfate,” Arzneimittel Forschung Drug Research 41:157-161, 1991.
Office Action mailed Mar. 17, 2008 in connection with U.S. Appl. No. 09/990,611, assigned to Bioderm, Inc.
Claims pending on Mar. 17, 2008 in connection with U.S. Appl. No. 09/990,611, assigned to Bioderm, Inc.
Office Action mailed Feb. 29, 2008 in connection with U.S. Appl. No. 09/997,663, assigned to Bioderm, Inc.
Claims pending on Feb. 29, 2008 in connection with U.S. Appl. No. 09/997,663, assigned to Bioderm, Inc.
Office Action mailed Jun. 13, 2006 in connection with U.S. Appl. No. 10/614,768, assigned to Bioderm, Inc., now abandoned.
Claims pending on Jun. 13, 2006 in connection with U.S. Appl. No. 10/614,768, assigned to Bioderm, Inc., now abandoned.
Office Action mailed Nov. 5, 2007 in connection with U.S. Appl. No. 11/389,384, assigned to Bioderm, Inc., now abandoned.
Claims pending on Nov. 5, 2007 in connection with U.S. Appl. No. 11/389,384, assigned to Bioderm, Inc., now abandoned.
Office Action mailed Nov. 2, 2007 in connection with U.S. Appl. No. 10/185,388, assigned to Bioderm, Inc.
Claims pending on Nov. 2, 2007 in connection with U.S. Appl. No. 10/185,388, assigned to Bioderm, Inc.
Ash, et al. Comparison of topical therapy for stiae alba (20% glycolic acid/0.05% tretinoin versus 20% glycolic acid/10% 1-ascorbic acid). 1998, Dermatol Sur g 24:849-856.
Austria, et al. Stability of vitamin C derivatives in solution and topical formulations. 1997, J Pharm. Biomed. Anal. 15:795-801.
Bandelin, et al, “The Stability of Ascorbic Acid in Various Liquid Media”, J. Am. Pharmacol. Assoc., 44(4), p. 241-244 (1955).
Bauerfeind. “Ascorbic Acid: Chemistry, Metabolism, Uses”, Seib, et al., Advances in Chemistry, pp. 417-429 (1982).
Bekesi, et al., “Inhibitory Effect of D-Glucosamine and Other Sugar Analogs on the Viability and Transplantability of Ascites Tumor Cells”, Cancer Research, 29, 353-359 (1969).
Black, H. S. “Potential Involvement of Free Radical Reactions in Ultraviolet Light-Mediated Cutaneous Damage”, Photochemistry and Photobiology, 46: 213-221 (1987).
Borne, et al., “Antiinflammatory Activity of Para-Substituted N-Benzenesulfonyl Derivatives of Amino Acids”, et al., J. Med. Chem., 15(12), 1325-1326 (1972).
Cooke, et al., “Vitamin C (Ascorbic Acid)”, from conference in Warwick, Coventry (Apr. 1981), pp. 167-168, 170-171, Published by Applied Science Publishers.
Edward Staunton West, Ph.D., Wilbert R. Todd, Ph.D., Howard S. Nason, Ph.D. and John T. Van Bruggen, Ph.D. “Textbook of biochemi.” Fourth Edition. 1966, pp. 823-795.
Englard, et al., “The Biochemical Functions of Ascorbic Acid”, Ann. Rev. Nutri., 6:365-406 (1986).
Gualano, et al., “Anti-inflammatory Activity of S-Adenosyl-L-Methionie: Interface with the Eicosanoid System”, Pharmacology Res. Commun., 15(7), 683-695 (Jul. 1983).
Hajratwala, B. R. “Stability of ascorbic acid”, B. R. Stability of ascorbic acid. S.T.P. Pharma, 1(4), 281-286 (1985).
Hall, et al., “Anti-Inflammatory Activity of Diazomethyl Ketone and Chloromethyl Ketone Analogs Prepared from N-Tosyl Amino Acids”, J. Pharm., 69(12), 1451-1452 (1989).
Hornig, et al., “Vitamin C (Ascorbic Acid)”, from conference in Warwick, Coventry (Apr. 1981), pp. 225-226, Published by Applied Science Publishers.
Imai, et al., “The Antiscorbutic Activity of L-Ascorbic Acid Phosphate Given Orally and Percutaneously in Guinea Pigs”, Jap. J. Pharmacol. Assoc., 317-324 (1967).
Jain, et al., “Evaluation of anti-inflammatory and analgesic properties of L-glutamine”, Agents and Actions, 11(3), 243-248 (1981).
Kahn, et al., “Ultraviolet Light Protection by Several New Compounds”, Arch Dermatol., 109, 510-517 (1974).
Kaplan, et al., “A New Stabilized Ascorbic Acid Solution: Percutaneous Absorption and Effect on Relative Collagen Synthsies”, J. Cutaneous Aging & Cosmetic Derm., 1(2), 115-121 (1988/89).
Kassem, et al., “Studies on the stability of injectable L-ascorbic acid solutions: III. Effect of metal-complexing agents”, Pharma. Acta Helvetiae, 47U, 89-97 (1972).
Kassem, et al., “Studies on the stability of injectable L-ascorbic acid solutions: I. Effect of pH , solvent, light and container”, Pharmaceutica Acta Helvetiae, 44, 611-623 (1969).
Kolata, G. “Is Tyrosine the Key to Growth Control?” Science, 219, 377-378 (1983).
Kunert, et al., “The Effect of Vitamin C on in vivo Lipid Peroxidation in Guinea Pigs as measured by Pentane and Ethane Production”, Lipids, 18, 271-273 (1983).
Kwapiszewski, et al., “Synthesis of L-Cysteine and S-Methyl-L-Cysteine Derivatives of Immunotropic and Anti-inflammatory Activity”, Arch. Immunol. Et Ther. Exp., 27(6), 729-731 (1979).
Laszlo, et al., “Effects o

Affiliated with

Also associated with

Rating

Compositions and methods for the treatment of skin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for the treatment of skin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of skin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4194617